Arterial Dissection-Lentiginosis Syndrome

Mendelian MONDO:0010889 Pathograph 9 Show in embeddings browser Vascular disorder

Arterial dissection-lentiginosis syndrome is an ultra-rare familial association syndrome reported in several members of two families. It is characterized by arterial dissection at an early age, multiple brown or black lentigines on the trunk and extremities, and cystic medial necrosis of affected arteries. Clinical manifestations vary with the arterial territory involved and can include headache, dysphasia, and hemiparesis. The mode of inheritance and causal gene remain unknown. A shared neural-crest or mesenchymal developmental defect has been proposed, but it is not an established mechanism.

Ask OpenScientist

Ask a research question about Arterial Dissection-Lentiginosis Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Definitions
1
Inheritance
3
Pathophys.
1
Histopath.
5
Phenotypes
9
Pathograph
1
Medical Actions
5
Differentials
2
Deep Research
🔗

Mappings

MONDO
MONDO:0010889 arterial dissection-lentiginosis syndrome
skos:exactMatch Orphadata ORPHA:1682 cross-reference record dated 2026-06-23
Orphadata lists MONDO:0010889 as a validated exact mapping for ORPHA:1682.
📘

Definitions

1
Orphanet clinical definition
An association of early arterial dissection, cystic medial necrosis, and multiple lentigines, with symptoms determined by the vascular territory involved.
OTHER
Show evidence (1 reference)
url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682 SUPPORT Other
"A rare association syndrome, reported in several members of two families to date, characterized by arterial dissection, occurring at an early age"
Orphadata provides the current syndrome-specific definition and its limited reported-family context.
👪

Inheritance

1
Unknown inheritance
Current Orphanet natural-history data classify inheritance as unknown. The familial presentation does not by itself establish autosomal recessive or autosomal dominant transmission, so neither mode is asserted.
Show evidence (1 reference)
url:https://api.orphadata.com/rd-natural_history/orphacodes/1682 SUPPORT Other
""Unknown""
Orphadata explicitly records the type of inheritance as unknown.
⚙

Pathophysiology

3
Putative neural-crest and mesenchymal developmental disturbance
A neurocristopathy-like developmental defect has been proposed to connect the vascular and pigmentary components. Available evidence is indirect and comes from a review of familial lentiginosis syndromes rather than an ADL-specific molecular or experimental study.
neurocristopathy hypothesis
neural crest cell CL:0011012 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neural crest cell (CL:0011012). CL:0011012 is a cell type from the Cell Ontology.
neural crest cell development GO:0014032 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal neural crest cell development (GO:0014032). GO:0014032 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Cystic medial degeneration and arterial-wall fragility The proposed model links abnormal neural-crest or mesenchymal development to medial structural disease, but the causal intermediates and ADL gene are unknown. neurocristopathy hypothesis
Putative melanocyte dysfunction Neural-crest-derived melanocyte dysfunction is proposed as the pigmentary branch of the same developmental hypothesis. neurocristopathy hypothesis
Show evidence (1 reference)
DOI:10.1046/j.1365-2796.1998.00341.x SUPPORT Human Clinical
"are involved in the function, growth and proliferation of neural crest and mesenchymal cells"
The review supplies biological plausibility across familial lentiginoses but does not establish this mechanism in ADL.
Cystic medial degeneration and arterial-wall fragility
Cystic medial necrosis is associated with affected arteries in the syndrome and provides a plausible structural substrate for dissection. The association is established, while its causal role and molecular basis remain provisional.
artery UBERON:0001637 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in artery (UBERON:0001637). UBERON:0001637 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Arterial dissection Medial degeneration is proposed to weaken the arterial wall and increase susceptibility to dissection; direct causality has not been tested.
Headache Headache can accompany dissection when a relevant cervicocephalic artery is involved.
Aphasia Dysphasia or aphasia can occur with neurovascular involvement.
Hemiparesis Hemiparesis can occur with neurovascular involvement.
Show evidence (1 reference)
url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682 SUPPORT Other
"in association with cystic medial necrosis and multiple lentigines"
The current Orphadata definition directly associates cystic medial necrosis with the syndrome.
Putative melanocyte dysfunction
Abnormal regulation of melanocyte function is a plausible explanation for the lentiginosis component, but no ADL-specific gene, signaling pathway, or cellular assay has established this mechanism.
melanocyte CL:0000148 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves melanocyte (CL:0000148). CL:0000148 is a cell type from the Cell Ontology.
Downstream
Multiple lentigines Dysregulated melanocyte behavior is proposed to produce the multiple lentigines.
Show evidence (1 reference)
DOI:10.1046/j.1365-2796.1998.00341.x SUPPORT Human Clinical
"genes responsible for the lentiginosis syndromes are important regulators of melanocyte function"
The review proposes melanocyte dysregulation across familial lentiginoses; it is not ADL-specific mechanistic evidence.
✶

Histopathology

1
Cystic medial necrosis
Cystic medial necrosis or degeneration of the arterial media is associated with the syndrome. It supports the arteriopathy interpretation but is not documented as pathognomonic and may be available only from operative or postmortem tissue.
Show evidence (1 reference)
url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682 SUPPORT Other
"in association with cystic medial necrosis and multiple lentigines"
Orphadata directly includes cystic medial necrosis in the syndrome definition.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Arterial Dissection-Lentiginosis Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Nervous System 3
Headache HP:0002315 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Headache (HP:0002315). HP:0002315 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682 SUPPORT Other
"headache, dysphasia, hemiparesis"
The current definition lists headache as an example of a vascular-territory-dependent manifestation.
Aphasia HP:0002381 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aphasia (HP:0002381). HP:0002381 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682 SUPPORT Other
"headache, dysphasia, hemiparesis"
Orphadata uses dysphasia; Aphasia is the corresponding HPO concept selected for this entry.
Hemiparesis Frequent HP:0001269 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hemiparesis (HP:0001269). HP:0001269 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682 SUPPORT Other
"headache, dysphasia, hemiparesis"
The current definition lists hemiparesis among territory-dependent manifestations.
url:https://api.orphadata.com/rd-phenotypes/orphacodes/1682 SUPPORT Other
""HPOFrequency": "Frequent (79-30%)""
The structured Orphadata HPO association classifies hemiparesis as frequent.
Other 2
Arterial dissection Very frequent HP:0005294 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Arterial dissection (HP:0005294). HP:0005294 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682 SUPPORT Other
"characterized by arterial dissection, occurring at an early age"
The current syndrome definition directly identifies early arterial dissection as a core feature.
url:https://api.orphadata.com/rd-phenotypes/orphacodes/1682 SUPPORT Other
""HPOFrequency": "Very frequent (99-80%)""
The Orphadata HPO association table classifies arterial dissection as very frequent.
Multiple lentigines HP:0001003 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Multiple lentigines (HP:0001003). HP:0001003 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682 SUPPORT Other
"multiple lentigines (brown and black in color and mainly affecting the skin of the trunk and extremities)"
Orphadata directly defines the morphology and distribution of the lentigines.
🗃️

External Assertions

1
Orphanet arterial dissection-lentiginosis syndrome record
Orphanet structured disease record ORPHA:1682
The current Orphadata record supplies the preferred name, clinical definition, exact MONDO and OMIM mappings, epidemiology, age of onset, inheritance status, and structured HPO associations used in this entry.
Show evidence (1 reference)
url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682 SUPPORT Other
""Preferred term": "Arterial dissection-lentiginosis syndrome""
The current Orphadata cross-reference record identifies ORPHA:1682 by the same preferred disease name.
💊

Medical Actions

1
Individualized antithrombotic therapy for cervical artery dissection
Category: Therapeutic
When ADL manifests as cervical artery dissection, antiplatelet or anticoagulant therapy may be considered using general cervical-dissection practice. Evidence does not establish a single preferred strategy, and ischemic benefit must be balanced against bleeding risk. This is territory-specific supportive management, not an ADL-specific or disease-modifying treatment.
Target Phenotypes: Arterial dissection HP:0005294 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Arterial dissection (HP:0005294). HP:0005294 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:38739383 SUPPORT Human Clinical
"found no significant difference between anticoagulants and antiplatelets in preventing early recurrent events"
Randomized-trial patient-level evidence does not establish superiority for the composite outcome.
PMID:38847098 SUPPORT Human Clinical
"This argues for an individualized therapeutic approach incorporating the net clinical benefit of ischemic stroke reduction and bleeding risks."
The broader meta-analysis supports individualized selection because anticoagulation reduced ischemic stroke but increased major bleeding.
🔬

Diagnosis

2
Syndromic clinical recognition
Diagnosis is clinical and rests on the unusual association of early arterial dissection, multiple lentigines, and cystic medial necrosis. No validated diagnostic criteria or syndrome-specific molecular confirmatory test were identified.
Results: Early arterial dissection plus characteristic multiple lentigines supports recognition of the syndrome; medial pathology may add corroboration when tissue is available.
Show evidence (1 reference)
url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682 SUPPORT Other
"characterized by arterial dissection, occurring at an early age and presenting with a range of manifestations depending on the vascular territory involved"
The Orphadata definition supplies the syndrome-defining clinical association.
Angiographic evaluation of suspected arterial dissection
Image symptomatic vascular territories to confirm dissection and define its extent. Magnetic resonance angiography is one option for cervical arterial involvement; modality and urgency should follow the affected territory and local acute-care practice.
angiography NCIT:C190556 NCI Thesaurus (NCIT)
Results: Demonstrates the site and extent of arterial dissection or related aneurysmal change.
Show evidence (1 reference)
PMID:11128183 SUPPORT Human Clinical
"Magnetic resonance imaging has largely surpassed angiography as the imaging study of choice."
General cervical-dissection evidence supports MR-based vascular imaging; no ADL-specific surveillance schedule is established.
🩻

Imaging Findings

1
Arterial dissection on angiographic imaging
Imaging can demonstrate dissection in the symptomatic arterial territory. The available cached diagnostic evidence is for spontaneous carotid and vertebral dissections generally, not for an ADL-specific screening protocol.
Angiography
Arterial dissection HP:0005294 Human Phenotype Ontology (HP)
Show evidence (1 reference)
PMID:11128183 SUPPORT Human Clinical
"Magnetic resonance imaging has largely surpassed angiography as the imaging study of choice."
The review supports MR-based diagnosis for cervical arterial dissection but is not syndrome-specific.
📈

Progression

2
Onset
Age: Childhood
Orphanet assigns childhood onset to the syndrome as a whole; the source does not provide a quantitative age distribution for individual findings.
Show evidence (1 reference)
url:https://api.orphadata.com/rd-natural_history/orphacodes/1682 SUPPORT Other
""Childhood""
Orphadata lists childhood as the average age-of-onset category.
Arterial dissection
Age: Early age, not further quantified
Dissection is episodic and its presentation depends on vascular territory; no syndrome-specific longitudinal natural-history series was identified.
Show evidence (1 reference)
url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682 SUPPORT Other
"arterial dissection, occurring at an early age and presenting with a range of manifestations depending on the vascular territory involved"
The current definition describes early dissection with territory-dependent manifestations.
📊

Prevalence

1
Worldwide
Point Prevalence ≤0.1 per 100,000 <1 in 1,000,000
Orphadata classifies worldwide point prevalence as below one per million and separately records four cases; its definition describes affected members of two families. These values reflect published case ascertainment, not a population survey.
Show evidence (2 references)
url:https://api.orphadata.com/rd-epidemiology/orphacodes/1682 SUPPORT Other
""PrevalenceClass": "<1 / 1 000 000""
Orphadata reports a validated worldwide point-prevalence class below one per million.
url:https://api.orphadata.com/rd-epidemiology/orphacodes/1682 SUPPORT Other
""ValMoy": "4.0""
The cases/families prevalence row records four published cases.
🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Arterial Dissection-Lentiginosis Syndrome:

Vascular Ehlers-Danlos syndrome
Overlapping Features Vascular Ehlers-Danlos syndrome can cause early arterial rupture or dissection and therefore overlaps with the vascular presentation.
Distinguishing Features
  • Pathogenic COL3A1 variants or abnormal type III procollagen support vascular Ehlers-Danlos syndrome.
  • Thin translucent skin, easy bruising, characteristic facial appearance, and intestinal or uterine rupture favor vascular Ehlers-Danlos syndrome rather than ADL.
  • Multiple lentigines are defining for ADL but are not a defining vascular Ehlers-Danlos feature.
Show evidence (1 reference)
PMID:28607545 SUPPORT Human Clinical
"The clinical diagnosis of vEDS, as per revised nosology of Villefranche, requires the presence of 2 of the following: (1) thin, translucent skin; (2) arterial, intestinal, or uterine rupture; (3) easy bruising"
The review provides vascular and extra-vascular features that distinguish vEDS from ADL.
Loeys-Dietz syndrome
Overlapping Features Loeys-Dietz syndrome is a syndromic arteriopathy with early, widespread aneurysm and dissection risk.
Distinguishing Features
  • A pathogenic variant in an established Loeys-Dietz pathway gene supports the diagnosis.
  • Bifid uvula or cleft palate, hypertelorism, craniosynostosis, and arterial tortuosity favor Loeys-Dietz syndrome.
  • Multiple lentigines and cystic medial necrosis as the named association favor ADL.
Show evidence (1 reference)
PMID:28607545 SUPPORT Human Clinical
"Loeys-Dietz syndrome type 1 is associated with craniofacial defects (bifid uvula, cleft palate, orbital hypertelorism, and craniosynostosis)"
The review describes discriminating craniofacial and molecular features of Loeys-Dietz syndrome.
Noonan syndrome with multiple lentigines
Overlapping Features Noonan syndrome with multiple lentigines overlaps through childhood-onset lentigines and cardiovascular disease but has a distinct RASopathy phenotype.
Distinguishing Features
  • Hypertrophic cardiomyopathy, characteristic facial features, conduction abnormalities, short stature, or deafness favor Noonan syndrome with multiple lentigines.
  • PTPN11 or another established RASopathy-gene variant supports the alternative diagnosis.
  • Early arterial dissection with cystic medial necrosis favors ADL.
Show evidence (1 reference)
PMID:16523510 SUPPORT Human Clinical
"LEOPARD syndrome (LS) is an autosomal dominant syndrome characterized by multiple lentigines and café-au-lait spots, electrocardiographic-conduction abnormalities, ocular hypertelorism/obstructive cardiomyopathy"
The clinical series identifies pigmentary and cardiac features that distinguish this RASopathy from ADL.
Peutz-Jeghers syndrome
Overlapping Features Peutz-Jeghers syndrome is a hereditary lentiginosis and multiple-neoplasia syndrome that can mimic the pigmentary component.
Distinguishing Features
  • Mucocutaneous pigmentation, hamartomatous gastrointestinal polyps, and an STK11 pathogenic variant favor Peutz-Jeghers syndrome.
  • Early arterial dissection and cystic medial necrosis favor ADL.
Show evidence (1 reference)
DOI:10.1159/000053283 SUPPORT Human Clinical
"are the two most common multiple neoplasia syndromes associated with lentiginosis."
The review establishes PJS as a major neoplasia-associated lentiginosis and identifies STK11 as its causal gene.
Carney complex
Overlapping Features Carney complex is a hereditary lentiginosis and multiple-neoplasia syndrome that can mimic the pigmentary component.
Distinguishing Features
  • Myxomas, endocrine overactivity or tumors, and a PRKAR1A pathogenic variant favor Carney complex.
  • Early arterial dissection with cystic medial necrosis favors ADL.
Show evidence (1 reference)
DOI:10.1159/000053283 SUPPORT Human Clinical
"are the two most common multiple neoplasia syndromes associated with lentiginosis."
The review establishes Carney complex as a major neoplasia-associated lentiginosis and describes its protein-kinase-A regulatory-subunit defect.
{ }

Source YAML

click to show 
name: Arterial Dissection-Lentiginosis Syndrome
creation_date: "2026-05-05T15:37:54Z"
description: >-
  Arterial dissection-lentiginosis syndrome is an ultra-rare familial
  association syndrome reported in several members of two families. It is
  characterized by arterial dissection at an early age, multiple brown or
  black lentigines on the trunk and extremities, and cystic medial necrosis of
  affected arteries. Clinical manifestations vary with the arterial territory
  involved and can include headache, dysphasia, and hemiparesis. The mode of
  inheritance and causal gene remain unknown. A shared neural-crest or
  mesenchymal developmental defect has been proposed, but it is not an
  established mechanism.
category: Mendelian
disease_term:
  preferred_term: arterial dissection-lentiginosis syndrome
  term:
    id: MONDO:0010889
    label: arterial dissection-lentiginosis syndrome
parents:
- Vascular disorder
synonyms:
- Aortic dissection lentiginosis
- Arterial dissections with lentiginosis
- Familial syndrome of arterial dissections with lentiginosis
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010889
      label: arterial dissection-lentiginosis syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: Orphadata ORPHA:1682 cross-reference record dated 2026-06-23
    mapping_justification: >-
      Orphadata lists MONDO:0010889 as a validated exact mapping for
      ORPHA:1682.
external_assertions:
- name: Orphanet arterial dissection-lentiginosis syndrome record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:1682
  url: https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
  description: >-
    The current Orphadata record supplies the preferred name, clinical
    definition, exact MONDO and OMIM mappings, epidemiology, age of onset,
    inheritance status, and structured HPO associations used in this entry.
  evidence:
  - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: '"Preferred term": "Arterial dissection-lentiginosis syndrome"'
    explanation: The current Orphadata cross-reference record identifies ORPHA:1682 by the same preferred disease name.
definitions:
- name: Orphanet clinical definition
  definition_type: OTHER
  description: >-
    An association of early arterial dissection, cystic medial necrosis, and
    multiple lentigines, with symptoms determined by the vascular territory
    involved.
  evidence:
  - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A rare association syndrome, reported in several members of two families
      to date, characterized by arterial dissection, occurring at an early age
    explanation: Orphadata provides the current syndrome-specific definition and its limited reported-family context.
inheritance:
- name: Unknown inheritance
  description: >-
    Current Orphanet natural-history data classify inheritance as unknown. The
    familial presentation does not by itself establish autosomal recessive or
    autosomal dominant transmission, so neither mode is asserted.
  evidence:
  - reference: url:https://api.orphadata.com/rd-natural_history/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-natural_history/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: '"Unknown"'
    explanation: Orphadata explicitly records the type of inheritance as unknown.
prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: BELOW_1_IN_1000000
  rate_high: 0.1
  percentage: "<1 per 1,000,000"
  notes: >-
    Orphadata classifies worldwide point prevalence as below one per million
    and separately records four cases; its definition describes affected
    members of two families. These values reflect published case ascertainment,
    not a population survey.
  evidence:
  - reference: url:https://api.orphadata.com/rd-epidemiology/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-epidemiology/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: '"PrevalenceClass": "<1 / 1 000 000"'
    explanation: Orphadata reports a validated worldwide point-prevalence class below one per million.
  - reference: url:https://api.orphadata.com/rd-epidemiology/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-epidemiology/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: '"ValMoy": "4.0"'
    explanation: The cases/families prevalence row records four published cases.
progression:
- phase: Onset
  age_range: Childhood
  notes: >-
    Orphanet assigns childhood onset to the syndrome as a whole; the source
    does not provide a quantitative age distribution for individual findings.
  evidence:
  - reference: url:https://api.orphadata.com/rd-natural_history/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-natural_history/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: '"Childhood"'
    explanation: Orphadata lists childhood as the average age-of-onset category.
- phase: Arterial dissection
  age_range: Early age, not further quantified
  notes: >-
    Dissection is episodic and its presentation depends on vascular territory;
    no syndrome-specific longitudinal natural-history series was identified.
  evidence:
  - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      arterial dissection, occurring at an early age and presenting with a
      range of manifestations depending on the vascular territory involved
    explanation: The current definition describes early dissection with territory-dependent manifestations.
pathophysiology:
- name: Putative neural-crest and mesenchymal developmental disturbance
  description: >-
    A neurocristopathy-like developmental defect has been proposed to connect
    the vascular and pigmentary components. Available evidence is indirect and
    comes from a review of familial lentiginosis syndromes rather than an
    ADL-specific molecular or experimental study.
  biological_scale: CELLULAR
  mechanism_confidence: HYPOTHETICAL
  cell_types:
  - preferred_term: neural crest cell
    term:
      id: CL:0011012
      label: neural crest cell
  biological_processes:
  - preferred_term: neural crest cell development
    modifier: ABNORMAL
    term:
      id: GO:0014032
      label: neural crest cell development
  evidence:
  - reference: DOI:10.1046/j.1365-2796.1998.00341.x
    reference_title: "Carney complex and the familial lentiginosis syndromes: link to inherited neoplasias and developmental disorders, and genetic loci"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      are involved in the function, growth and proliferation of neural crest
      and mesenchymal cells
    explanation: The review supplies biological plausibility across familial lentiginoses but does not establish this mechanism in ADL.
  downstream:
  - target: Cystic medial degeneration and arterial-wall fragility
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - neurocristopathy_hypothesis
    description: >-
      The proposed model links abnormal neural-crest or mesenchymal development
      to medial structural disease, but the causal intermediates and ADL gene
      are unknown.
    evidence:
    - reference: DOI:10.1046/j.1365-2796.1998.00341.x
      reference_title: "Carney complex and the familial lentiginosis syndromes: link to inherited neoplasias and developmental disorders, and genetic loci"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        are involved in the function, growth and proliferation of neural crest
        and mesenchymal cells
      explanation: The review supports the developmental hypothesis only indirectly and does not demonstrate an artery-specific edge.
  - target: Putative melanocyte dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - neurocristopathy_hypothesis
    description: >-
      Neural-crest-derived melanocyte dysfunction is proposed as the pigmentary
      branch of the same developmental hypothesis.
    evidence:
    - reference: DOI:10.1046/j.1365-2796.1998.00341.x
      reference_title: "Carney complex and the familial lentiginosis syndromes: link to inherited neoplasias and developmental disorders, and genetic loci"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        important regulators of melanocyte function, they participate in the
        pleiotropy of human pigmentation
      explanation: The review proposes melanocyte regulation across lentiginosis syndromes but does not identify the ADL-specific molecular bridge.
- name: Cystic medial degeneration and arterial-wall fragility
  description: >-
    Cystic medial necrosis is associated with affected arteries in the syndrome
    and provides a plausible structural substrate for dissection. The
    association is established, while its causal role and molecular basis
    remain provisional.
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  locations:
  - preferred_term: artery
    term:
      id: UBERON:0001637
      label: artery
  evidence:
  - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: in association with cystic medial necrosis and multiple lentigines
    explanation: The current Orphadata definition directly associates cystic medial necrosis with the syndrome.
  downstream:
  - target: Arterial dissection
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Medial degeneration is proposed to weaken the arterial wall and increase
      susceptibility to dissection; direct causality has not been tested.
    evidence:
    - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
      reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        characterized by arterial dissection, occurring at an early age and
        presenting with a range of manifestations depending on the vascular
        territory involved
      explanation: Orphadata supports co-occurrence of early dissection and medial pathology, while causal direction remains inferred.
  - target: Headache
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - arterial dissection in a cervicocephalic territory
    - local vascular pain or impaired cerebral perfusion
    description: Headache can accompany dissection when a relevant cervicocephalic artery is involved.
    evidence:
    - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
      reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: headache, dysphasia, hemiparesis
      explanation: Orphadata lists headache among territory-dependent presentations of early arterial dissection.
  - target: Aphasia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - arterial dissection in a cervicocephalic territory
    - focal cerebral hypoperfusion or ischemia
    description: Dysphasia or aphasia can occur with neurovascular involvement.
    evidence:
    - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
      reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: headache, dysphasia, hemiparesis
      explanation: Orphadata lists dysphasia among territory-dependent manifestations; Aphasia is the corresponding HPO concept.
  - target: Hemiparesis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - arterial dissection in a cervicocephalic territory
    - focal cerebral hypoperfusion or ischemia
    description: Hemiparesis can occur with neurovascular involvement.
    evidence:
    - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
      reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: headache, dysphasia, hemiparesis
      explanation: Orphadata lists hemiparesis among territory-dependent manifestations of arterial dissection.
- name: Putative melanocyte dysfunction
  description: >-
    Abnormal regulation of melanocyte function is a plausible explanation for
    the lentiginosis component, but no ADL-specific gene, signaling pathway, or
    cellular assay has established this mechanism.
  biological_scale: CELLULAR
  mechanism_confidence: HYPOTHETICAL
  cell_types:
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  evidence:
  - reference: DOI:10.1046/j.1365-2796.1998.00341.x
    reference_title: "Carney complex and the familial lentiginosis syndromes: link to inherited neoplasias and developmental disorders, and genetic loci"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      genes responsible for the lentiginosis syndromes are important regulators
      of melanocyte function
    explanation: The review proposes melanocyte dysregulation across familial lentiginoses; it is not ADL-specific mechanistic evidence.
  downstream:
  - target: Multiple lentigines
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Dysregulated melanocyte behavior is proposed to produce the multiple lentigines.
    evidence:
    - reference: DOI:10.1046/j.1365-2796.1998.00341.x
      reference_title: "Carney complex and the familial lentiginosis syndromes: link to inherited neoplasias and developmental disorders, and genetic loci"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        important regulators of melanocyte function, they participate in the
        pleiotropy of human pigmentation
      explanation: The review supports a pigment-cell hypothesis but does not demonstrate the causal edge in ADL.
phenotypes:
- category: Cardiovascular
  name: Arterial dissection
  frequency: Very frequent
  diagnostic: true
  description: Early arterial dissection is the defining vascular manifestation; symptoms depend on the involved arterial territory.
  phenotype_term:
    preferred_term: Arterial dissection
    term:
      id: HP:0005294
      label: Arterial dissection
  evidence:
  - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: characterized by arterial dissection, occurring at an early age
    explanation: The current syndrome definition directly identifies early arterial dissection as a core feature.
  - reference: url:https://api.orphadata.com/rd-phenotypes/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-phenotypes/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: '"HPOFrequency": "Very frequent (99-80%)"'
    explanation: The Orphadata HPO association table classifies arterial dissection as very frequent.
- category: Integumentary
  name: Multiple lentigines
  diagnostic: true
  description: Multiple brown and black lentigines mainly affect the trunk and extremities and define the pigmentary component.
  phenotype_term:
    preferred_term: Multiple lentigines
    term:
      id: HP:0001003
      label: Multiple lentigines
  evidence:
  - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      multiple lentigines (brown and black in color and mainly affecting the
      skin of the trunk and extremities)
    explanation: Orphadata directly defines the morphology and distribution of the lentigines.
- category: Neurologic
  name: Headache
  description: Headache is a territory-dependent presentation of arterial dissection.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: headache, dysphasia, hemiparesis
    explanation: The current definition lists headache as an example of a vascular-territory-dependent manifestation.
- category: Neurologic
  name: Aphasia
  description: Dysphasia or aphasia is a territory-dependent neurologic presentation of arterial dissection.
  phenotype_term:
    preferred_term: Aphasia
    term:
      id: HP:0002381
      label: Aphasia
  evidence:
  - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: headache, dysphasia, hemiparesis
    explanation: Orphadata uses dysphasia; Aphasia is the corresponding HPO concept selected for this entry.
- category: Neurologic
  name: Hemiparesis
  frequency: Frequent
  description: Hemiparesis is a territory-dependent neurologic presentation of arterial dissection.
  phenotype_term:
    preferred_term: Hemiparesis
    term:
      id: HP:0001269
      label: Hemiparesis
  evidence:
  - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: headache, dysphasia, hemiparesis
    explanation: The current definition lists hemiparesis among territory-dependent manifestations.
  - reference: url:https://api.orphadata.com/rd-phenotypes/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-phenotypes/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: '"HPOFrequency": "Frequent (79-30%)"'
    explanation: The structured Orphadata HPO association classifies hemiparesis as frequent.
histopathology:
- name: Cystic medial necrosis
  description: >-
    Cystic medial necrosis or degeneration of the arterial media is associated
    with the syndrome. It supports the arteriopathy interpretation but is not
    documented as pathognomonic and may be available only from operative or
    postmortem tissue.
  diagnostic: false
  evidence:
  - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: in association with cystic medial necrosis and multiple lentigines
    explanation: Orphadata directly includes cystic medial necrosis in the syndrome definition.
imaging_findings:
- name: Arterial dissection on angiographic imaging
  modality: ANGIOGRAPHY
  description: >-
    Imaging can demonstrate dissection in the symptomatic arterial territory.
    The available cached diagnostic evidence is for spontaneous carotid and
    vertebral dissections generally, not for an ADL-specific screening protocol.
  phenotype_term:
    preferred_term: Arterial dissection
    term:
      id: HP:0005294
      label: Arterial dissection
  diagnostic: false
  evidence:
  - reference: PMID:11128183
    reference_title: The treatment of spontaneous carotid and vertebral artery dissections.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Magnetic resonance imaging has largely surpassed angiography as the imaging study of choice.
    explanation: The review supports MR-based diagnosis for cervical arterial dissection but is not syndrome-specific.
diagnosis:
- name: Syndromic clinical recognition
  description: >-
    Diagnosis is clinical and rests on the unusual association of early
    arterial dissection, multiple lentigines, and cystic medial necrosis. No
    validated diagnostic criteria or syndrome-specific molecular confirmatory
    test were identified.
  results: Early arterial dissection plus characteristic multiple lentigines supports recognition of the syndrome; medial pathology may add corroboration when tissue is available.
  evidence:
  - reference: url:https://api.orphadata.com/rd-cross-referencing/orphacodes/1682
    reference_title: "https://api.orphadata.com/rd-cross-referencing/orphacodes/1682"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      characterized by arterial dissection, occurring at an early age and
      presenting with a range of manifestations depending on the vascular
      territory involved
    explanation: The Orphadata definition supplies the syndrome-defining clinical association.
- name: Angiographic evaluation of suspected arterial dissection
  description: >-
    Image symptomatic vascular territories to confirm dissection and define
    its extent. Magnetic resonance angiography is one option for cervical
    arterial involvement; modality and urgency should follow the affected
    territory and local acute-care practice.
  diagnosis_term:
    preferred_term: angiography
    term:
      id: NCIT:C190556
      label: Angiography
  results: Demonstrates the site and extent of arterial dissection or related aneurysmal change.
  evidence:
  - reference: PMID:11128183
    reference_title: The treatment of spontaneous carotid and vertebral artery dissections.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Magnetic resonance imaging has largely surpassed angiography as the imaging study of choice.
    explanation: General cervical-dissection evidence supports MR-based vascular imaging; no ADL-specific surveillance schedule is established.
differential_diagnoses:
- name: Vascular Ehlers-Danlos syndrome
  description: >-
    Vascular Ehlers-Danlos syndrome can cause early arterial rupture or
    dissection and therefore overlaps with the vascular presentation.
  distinguishing_features:
  - Pathogenic COL3A1 variants or abnormal type III procollagen support vascular Ehlers-Danlos syndrome.
  - Thin translucent skin, easy bruising, characteristic facial appearance, and intestinal or uterine rupture favor vascular Ehlers-Danlos syndrome rather than ADL.
  - Multiple lentigines are defining for ADL but are not a defining vascular Ehlers-Danlos feature.
  evidence:
  - reference: PMID:28607545
    reference_title: The Genetics of Aortopathies in Clinical Cardiology.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical diagnosis of vEDS, as per revised nosology of Villefranche,
      requires the presence of 2 of the following: (1) thin, translucent skin;
      (2) arterial, intestinal, or uterine rupture; (3) easy bruising
    explanation: The review provides vascular and extra-vascular features that distinguish vEDS from ADL.
- name: Loeys-Dietz syndrome
  description: Loeys-Dietz syndrome is a syndromic arteriopathy with early, widespread aneurysm and dissection risk.
  distinguishing_features:
  - A pathogenic variant in an established Loeys-Dietz pathway gene supports the diagnosis.
  - Bifid uvula or cleft palate, hypertelorism, craniosynostosis, and arterial tortuosity favor Loeys-Dietz syndrome.
  - Multiple lentigines and cystic medial necrosis as the named association favor ADL.
  evidence:
  - reference: PMID:28607545
    reference_title: The Genetics of Aortopathies in Clinical Cardiology.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Loeys-Dietz syndrome type 1 is associated with craniofacial defects
      (bifid uvula, cleft palate, orbital hypertelorism, and craniosynostosis)
    explanation: The review describes discriminating craniofacial and molecular features of Loeys-Dietz syndrome.
- name: Noonan syndrome with multiple lentigines
  description: >-
    Noonan syndrome with multiple lentigines overlaps through childhood-onset
    lentigines and cardiovascular disease but has a distinct RASopathy phenotype.
  distinguishing_features:
  - Hypertrophic cardiomyopathy, characteristic facial features, conduction abnormalities, short stature, or deafness favor Noonan syndrome with multiple lentigines.
  - PTPN11 or another established RASopathy-gene variant supports the alternative diagnosis.
  - Early arterial dissection with cystic medial necrosis favors ADL.
  evidence:
  - reference: PMID:16523510
    reference_title: "LEOPARD syndrome: clinical diagnosis in the first year of life."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LEOPARD syndrome (LS) is an autosomal dominant syndrome characterized by
      multiple lentigines and café-au-lait spots, electrocardiographic-conduction
      abnormalities, ocular hypertelorism/obstructive cardiomyopathy
    explanation: The clinical series identifies pigmentary and cardiac features that distinguish this RASopathy from ADL.
- name: Peutz-Jeghers syndrome
  description: Peutz-Jeghers syndrome is a hereditary lentiginosis and multiple-neoplasia syndrome that can mimic the pigmentary component.
  distinguishing_features:
  - Mucocutaneous pigmentation, hamartomatous gastrointestinal polyps, and an STK11 pathogenic variant favor Peutz-Jeghers syndrome.
  - Early arterial dissection and cystic medial necrosis favor ADL.
  evidence:
  - reference: DOI:10.1159/000053283
    reference_title: Genetics of Peutz-Jeghers Syndrome, Carney Complex and Other Familial Lentiginoses
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      are the two most common multiple neoplasia syndromes associated with
      lentiginosis.
    explanation: The review establishes PJS as a major neoplasia-associated lentiginosis and identifies STK11 as its causal gene.
- name: Carney complex
  description: Carney complex is a hereditary lentiginosis and multiple-neoplasia syndrome that can mimic the pigmentary component.
  distinguishing_features:
  - Myxomas, endocrine overactivity or tumors, and a PRKAR1A pathogenic variant favor Carney complex.
  - Early arterial dissection with cystic medial necrosis favors ADL.
  evidence:
  - reference: DOI:10.1159/000053283
    reference_title: Genetics of Peutz-Jeghers Syndrome, Carney Complex and Other Familial Lentiginoses
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      are the two most common multiple neoplasia syndromes associated with
      lentiginosis.
    explanation: The review establishes Carney complex as a major neoplasia-associated lentiginosis and describes its protein-kinase-A regulatory-subunit defect.
treatments:
- name: Individualized antithrombotic therapy for cervical artery dissection
  action_category: THERAPEUTIC
  description: >-
    When ADL manifests as cervical artery dissection, antiplatelet or
    anticoagulant therapy may be considered using general cervical-dissection
    practice. Evidence does not establish a single preferred strategy, and
    ischemic benefit must be balanced against bleeding risk. This is
    territory-specific supportive management, not an ADL-specific or
    disease-modifying treatment.
  target_phenotypes:
  - preferred_term: Arterial dissection
    term:
      id: HP:0005294
      label: Arterial dissection
  evidence:
  - reference: PMID:38739383
    reference_title: "Antithrombotic Treatment for Cervical Artery Dissection: A Systematic Review and Individual Patient Data Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      found no significant difference between anticoagulants and antiplatelets
      in preventing early recurrent events
    explanation: Randomized-trial patient-level evidence does not establish superiority for the composite outcome.
  - reference: PMID:38847098
    reference_title: "Anticoagulation Versus Antiplatelets in Spontaneous Cervical Artery Dissection: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This argues for an individualized therapeutic approach incorporating the
      net clinical benefit of ischemic stroke reduction and bleeding risks.
    explanation: The broader meta-analysis supports individualized selection because anticoagulation reduced ischemic stroke but increased major bleeding.
  notes: >-
    No syndrome-specific treatment trial, prophylactic regimen, or surveillance
    interval was identified. Aortic, intracranial, and visceral dissections
    require urgent management according to their own vascular territory and are
    not covered by the cervical-dissection antithrombotic evidence above.
review_notes: >-
  Reviewed against Orphadata records dated 2026-06-23 and the locally cached
  literature. Current Orphanet data explicitly classify inheritance as unknown;
  autosomal recessive inheritance is therefore not asserted. No causal gene or
  ADL-specific molecular test was identified, so the former placeholder
  "Unknown causal gene" genetic record was removed rather than modeled as a
  negative gene association. The original report cache (PMID:7838191) contains
  title and MEDLINE metadata but no abstract or full text; aortic dissection and
  intracranial aneurysm are consequently not promoted to curated phenotypes.
  The neural-crest/mesenchymal and melanocyte model remains HYPOTHETICAL, while
  cystic medial degeneration is modeled as a PROVISIONAL causal substrate despite
  its established clinical association. The 2016 Orphadata HPO export also lists
  melanocytic nevus and arteriovenous malformation; neither was promoted because
  those mappings are not corroborated by the current definition or accessible
  primary text; they remain source leads rather than curated phenotype records.
  Imaging and antithrombotic entries are explicitly extrapolated
  from general cervical arterial-dissection evidence; there are no validated
  ADL-specific diagnostic criteria, surveillance schedule, or disease-modifying
  treatment data.
📚

References & Deep Research

Deep Research

2
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 16 citations 2026-05-05T11:53:27.764410

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Arterial Dissection-Lentiginosis Syndrome
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Arterial Dissection-Lentiginosis Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Arterial Dissection–Lentiginosis Syndrome (ADL)

Executive summary

Arterial Dissections with Lentiginosis (ADL) is a very rare, primarily case-report–defined Mendelian syndrome characterized by early-onset, sometimes recurrent, dissections of large/medium arteries together with multiple cutaneous lentigines and arterial wall pathology consistent with cystic medial degeneration/necrosis. The condition was initially described in two families (two sibling pairs) in a Mayo Clinic arterial-dissection cohort, and subsequent reviews mention six additional sporadic cases. A causal gene has not been identified in the retrieved primary literature; one family had negative testing for type III procollagen abnormalities (COL3A1) in cultured fibroblasts. A prominent mechanistic hypothesis proposes a neural-crest developmental defect (“neurocristopathy”) linking melanocyte abnormalities to arterial tunica media fragility. (schievink1995briefreporta pages 1-1, schievink1995briefreporta pages 1-3, schievink1995briefreporta pages 3-4)

Artifact: consolidated snapshot

The following table is a knowledge-base–ready synopsis of identifiers, phenotypes, inheritance, and molecular status.

Aspect Summary Evidence type Citation
Disease / synonyms Arterial dissections with lentiginosis (ADL); familial syndrome of arterial dissections with lentiginosis; also referred to as arterial dissection-lentiginosis syndrome in secondary summaries. Human case report; review (schievink1995briefreporta pages 1-1, chrousos1998carneycomplexand pages 4-4)
Key identifiers OMIM: 600459; listed among familial lentiginoses in review tables. No gene assignment was identified in the cited sources. Review (stratakis2001geneticsofpeutzjeghers pages 1-3, chrousos1998carneycomplexand pages 1-2)
Reported cases / count Originally described in 2 sibling pairs from a Mayo Clinic series of 240 arterial-dissection patients; 6 additional sporadic cases were later noted in reviews. Human case report; review (schievink1995briefreporta pages 1-1, stratakis2001geneticsofpeutzjeghers pages 6-8, chrousos1998carneycomplexand pages 4-4)
Inheritance Autosomal recessive suggested because of lack of vertical transmission and consanguinity in one family; autosomal dominant inheritance with variable penetrance/expression not excluded. Human case report; review (schievink1995briefreporta pages 1-3, stratakis2001geneticsofpeutzjeghers pages 6-8)
Key vascular features Predisposition to dissections of large/medium arteries, especially the aorta, renal artery, and extracranial internal carotid artery; vertebral/cervical artery dissections and recurrent/multivessel involvement were reported in the original families. Human case report; review (schievink1995briefreporta pages 1-3, schievink1995briefreporta pages 3-4, stratakis2001geneticsofpeutzjeghers pages 6-8)
Key skin features Multiple lentigines, typically 2–4 mm, dark brown to black, on trunk and extremities (especially lower legs); may occur on sun-exposed and non-sun-exposed skin; lesions usually begin in childhood; mucous membranes spared in reported families. Human case report; review (schievink1995briefreporta pages 1-3, schievink1995briefreporta pages 3-4, fikar2000etiologicfactorsof pages 4-6)
Pathology Arterial pathology showed cystic medial necrosis / cystic medial degeneration and elastin abnormalities; one resected artery showed acute medial dissection with focal cystic degeneration of the media. Human case report; review (schievink1995briefreporta pages 1-3, schievink1995briefreporta pages 3-4, fikar2000etiologicfactorsof pages 4-6)
Mechanistic hypothesis Proposed developmental mechanism is a neural crest defect / neurocristopathy, because melanocytes and the tunica media of the aortic arch and its branches derive from neural crest; chick neural crest ablation produced similar elastin disarray. Human case report; review (schievink1995briefreporta pages 3-4, fikar2000etiologicfactorsof pages 4-6)
Molecular genetics status No causal gene or pathogenic variant identified in the cited ADL literature; COL3A1/type III procollagen abnormalities were not found in tested fibroblasts from one family, and ADL-specific locus/gene remained unknown in reviews. Human case report; review (schievink1995briefreporta pages 1-3, stratakis2001geneticsofpeutzjeghers pages 9-10, chrousos1998carneycomplexand pages 1-2)

Table: This table consolidates the key published facts about Arterial Dissections with Lentiginosis (ADL) syndrome from the original 1995 case report and subsequent reviews. It is useful as a knowledge-base-ready snapshot of identifiers, phenotype, inheritance, pathology, and current molecular uncertainty.

1. Disease information

1.1 What is the disease?

ADL (Arterial Dissections with Lentiginosis) is a syndromic arteriopathy in which affected individuals develop arterial dissections (cervical/cerebrovascular and systemic large arteries including aorta and renal arteries) at relatively young ages, along with multiple lentigines (small, dark brown-to-black macules) that typically appear in childhood and may fade later. In the original report, arterial histopathology showed cystic medial necrosis/degeneration. (schievink1995briefreporta pages 1-3, schievink1995briefreporta pages 3-4)

1.2 Key identifiers

  • OMIM: 600459 (listed under familial lentiginoses as “arterial dissections and lentiginosis (ADL)” in a genetics review). (stratakis2001geneticsofpeutzjeghers pages 1-3)
  • Mondo / Orphanet / MeSH / ICD-10/ICD-11: Not found in the retrieved corpus; these identifiers may exist in external curated resources but could not be verified here.

1.3 Synonyms / alternative names

  • “A familial syndrome of arterial dissections with lentiginosis” (original NEJM description). (schievink1995briefreporta pages 1-1)
  • “Arterial dissections and lentiginosis (ADL) syndrome” (review terminology). (stratakis2001geneticsofpeutzjeghers pages 6-8)

1.4 Evidence source type

The ADL entity in the retrieved sources is derived from: - Primary human case reports (families; NEJM 1995). (schievink1995briefreporta pages 1-1, schievink1995briefreporta pages 1-3) - Aggregated review resources summarizing those cases and additional sporadic reports. (stratakis2001geneticsofpeutzjeghers pages 6-8, chrousos1998carneycomplexand pages 4-4)

Publication details / URLs (primary sources): - Schievink WI et al. N Engl J Med (1995-03-02). DOI/URL: https://doi.org/10.1056/NEJM199503023320905 (schievink1995briefreporta pages 1-1) - Stratakis CA. Horm Res (2001-09). DOI/URL: https://doi.org/10.1159/000053283 (stratakis2001geneticsofpeutzjeghers pages 6-8) - Chrousos GP, Stratakis CA. J Intern Med (1998-06). DOI/URL: https://doi.org/10.1046/j.1365-2796.1998.00341.x (chrousos1998carneycomplexand pages 1-2)

2. Etiology

2.1 Disease causal factors

Genetic cause: The causal gene is unknown in the retrieved primary literature and reviews; ADL is suspected to be genetic due to familial clustering and early presentation. (schievink1995briefreporta pages 1-3, chrousos1998carneycomplexand pages 1-2)

Mechanistic etiology (developmental hypothesis): A proposed etiology is a defect in neural-crest–derived lineages (“neurocristopathy”), because melanocytes derive from trunk neural crest and the tunica media of the aortic arch/branches derives from cranial neural crest; this developmental link was used to explain the co-occurrence of lentigines and cystic medial necrosis/dissection. (schievink1995briefreporta pages 3-4, fikar2000etiologicfactorsof pages 4-6)

2.2 Risk factors

  • Family history: Familial occurrence is central to the syndrome definition. In one series context, “8 of ~240” cervical-artery dissection patients had family history, motivating identification of the two ADL families. (schievink1995briefreporta pages 1-1)
  • Trauma: At least one cervical dissection case in the original report occurred after a skiing accident; a separate dissection (occipital artery) was thought related to surgery/operation exposure rather than spontaneous disease biology. These observations suggest that mechanical triggers may precipitate events in a predisposed arterial wall, but this is not quantified as a risk factor specific to ADL. (schievink1995briefreporta pages 1-1, schievink1995briefreporta pages 1-3)

2.3 Protective factors

No ADL-specific protective factors were identified in the retrieved sources.

2.4 Gene–environment interaction

Not established for ADL in the retrieved sources.

3. Phenotypes

3.1 Core phenotype domains

A) Vascular phenotypes (clinical signs/symptoms)

  • Arterial dissection in multiple vascular beds, including:
  • Extracranial internal carotid artery dissection (angiographic stenosis consistent with dissection). (schievink1995briefreporta pages 1-3)
  • Cervical vertebral artery dissection (original cases). (schievink1995briefreporta pages 1-1)
  • Ascending aortic dissection/rupture causing sudden death in a relative (autopsy hemopericardium; cystic medial necrosis). (schievink1995briefreporta pages 1-1, schievink1995briefreporta pages 3-4)
  • Reviews also emphasize predisposition to dissections of aorta, renal artery, extracranial internal carotid artery. (stratakis2001geneticsofpeutzjeghers pages 6-8, chrousos1998carneycomplexand pages 4-4)
  • Associated neurologic presentations in cervical dissections included headache and focal deficits (e.g., hemiparesis), consistent with typical cervicocephalic dissection presentations (reported within the family). (schievink1995briefreporta pages 1-1, schievink1995briefreporta pages 1-3)

Suggested HPO terms (mapping to described features): - Arterial dissection: HP:0004970 (arterial dissection; general) - Aortic dissection: HP:0002647 - Carotid artery dissection: HP:0030809 (if using specific term; otherwise arterial dissection) - Vertebral artery dissection: (may be represented via arterial dissection plus vertebral artery involvement term if available) - Recurrent arterial dissections: (use recurrence qualifier if present)

B) Dermatologic phenotypes

  • Multiple lentigines (lentiginosis): described as “flat or slightly raised…brown-to-black…2 to 4 mm,” often present on trunk and extremities, particularly lower legs, and also reported on palms and soles in the case report narrative summary. Lentigines begin in childhood, increase in adolescence/early adulthood, and may fade. (schievink1995briefreporta pages 1-3, schievink1995briefreporta pages 3-4)
  • Mucosal sparing: mucous membranes were spared in the NEJM families, helping distinguish from Carney complex in the differential. (schievink1995briefreporta pages 3-4)

Suggested HPO terms: - Multiple lentigines: HP:0001003 - Hyperpigmented macules: HP:0001013

C) Structural cardiovascular phenotype

  • Aortic coarctation occurred in one patient in the original report. (schievink1995briefreporta pages 3-4)

Suggested HPO term: - Coarctation of the aorta: HP:0001680

3.2 Phenotype characteristics (onset, severity, progression, frequency)

  • Age of onset: Lentigines “usually appear in childhood”; vascular dissections occurred at “young age” in affected members, including a 25-year-old brother with carotid dissection and a 22-year-old with ascending aortic dissection noted in secondary review. (schievink1995briefreporta pages 1-3, fikar2000etiologicfactorsof pages 4-6)
  • Progression/course: Vascular course can be multivessel and recurrent; follow-up in one case noted no vascular events over eight years and fading lentigines. (schievink1995briefreporta pages 1-3)
  • Frequency: No reliable penetrance/frequency estimates exist due to very small case counts; reviews cite two sibling pairs and six sporadic cases. (stratakis2001geneticsofpeutzjeghers pages 6-8, chrousos1998carneycomplexand pages 4-4)

3.3 Quality-of-life impact

Not directly measured with QoL instruments in retrieved literature; major impact is inferred from risk of stroke-like events and fatal aortic rupture. (schievink1995briefreporta pages 1-1, schievink1995briefreporta pages 3-4)

4. Genetic / molecular information

4.1 Causal genes

Unknown in the retrieved ADL literature. (chrousos1998carneycomplexand pages 1-2)

4.2 Pathogenic variants

No ADL-specific pathogenic variant(s) were reported in the retrieved texts.

4.3 Relevant negative finding (candidate exclusion)

The NEJM report states that “analysis of the type III procollagen gene in cultured skin fibroblasts showed no abnormalities,” arguing against COL3A1-mediated vascular Ehlers–Danlos as an explanation in that family. (schievink1995briefreporta pages 1-3)

4.4 Functional consequences

Not established for ADL (no gene identified).

4.5 Modifier genes / epigenetics / chromosomal abnormalities

Not reported for ADL in the retrieved sources.

5. Environmental information

No ADL-specific environmental contributors were identified. Individual dissections may be precipitated by trauma or iatrogenic factors in susceptible vessels, but this is not established as syndrome-specific epidemiology. (schievink1995briefreporta pages 1-1, schievink1995briefreporta pages 1-3)

6. Mechanism / pathophysiology

6.1 Proposed causal chain (current best-supported hypothesis)

  1. Developmental defect in neural-crest–derived cells (hypothesized genetic). (schievink1995briefreporta pages 3-4)
  2. Abnormal arterial tunica media / extracellular matrix organization manifested as cystic medial necrosis/degeneration and elastin fiber disarray. (schievink1995briefreporta pages 3-4, fikar2000etiologicfactorsof pages 4-6)
  3. Mechanical failure of arterial wall under physiologic or triggered stress → arterial dissection across multiple vascular beds (cervicocephalic, renal, aortic). (stratakis2001geneticsofpeutzjeghers pages 6-8, schievink1995briefreporta pages 1-3)
  4. Parallel phenotype: altered melanocyte development/migration → multiple cutaneous lentigines. (schievink1995briefreporta pages 3-4)

6.2 Upstream vs downstream

  • Upstream: suspected developmental/genetic defect; neural crest lineage biology. (schievink1995briefreporta pages 3-4)
  • Downstream: cystic medial necrosis and clinical dissections; neurologic sequelae or sudden death. (schievink1995briefreporta pages 1-1, schievink1995briefreporta pages 3-4)

6.3 Cell types (CL suggestions)

  • Melanocyte: CL:0000148 (lentigines biology). (schievink1995briefreporta pages 3-4)
  • Vascular smooth muscle cell (arterial media): CL term for vascular SMC (arterial wall integrity) (mechanistically implied by tunica media pathology). (schievink1995briefreporta pages 3-4)

6.4 GO biological process suggestions (hypothesis-driven)

Given the neurocristopathy hypothesis and medial degeneration pathology, plausible GO process annotations include: - Neural crest cell migration / development (e.g., “neural crest cell migration”). (schievink1995briefreporta pages 3-4) - Extracellular matrix organization / elastic fiber formation (consistent with elastin disarray). (schievink1995briefreporta pages 3-4)

6.5 Molecular profiling / omics

No transcriptomic/proteomic/metabolomic studies were identified for ADL.

7. Anatomical structures affected

7.1 Organ/system level

  • Cardiovascular system: aorta; renal arteries; extracranial internal carotid arteries; vertebral/cervical arteries. (stratakis2001geneticsofpeutzjeghers pages 6-8, schievink1995briefreporta pages 1-3)
  • Integumentary system: skin (lentigines on trunk/extremities, palms/soles; mucosa spared). (schievink1995briefreporta pages 1-3, schievink1995briefreporta pages 3-4)

7.2 Tissue/cell level

  • Arterial tunica media (site of cystic medial necrosis). (schievink1995briefreporta pages 3-4)
  • Melanocyte-containing epidermal/dermal junction (lentigines histology referenced in NEJM discussion). (schievink1995briefreporta pages 3-4)

7.3 UBERON suggestions

  • Aorta: UBERON:0000947
  • Renal artery: UBERON:0001496
  • Internal carotid artery: UBERON:0004451
  • Skin of lower limb: UBERON:0004264 (or more specific lower leg skin term)

8. Temporal development

  • Onset pattern: lentigines in childhood; dissections in adolescence/young adulthood in reported kindreds. (schievink1995briefreporta pages 3-4, schievink1995briefreporta pages 1-3)
  • Course: variable; potential for recurrent and multivessel dissections; at least one case had stable follow-up (8 years) without further vascular events and fading lentigines. (schievink1995briefreporta pages 1-3)

9. Inheritance and population

9.1 Inheritance

  • The NEJM case report argues the syndrome is “genetic in origin,” and suggests autosomal recessive inheritance due to absent vertical transmission and consanguinity in one family, while not excluding autosomal dominant inheritance with variable penetrance/expression. (schievink1995briefreporta pages 1-3)
  • Reviews maintain that inheritance is “not clear,” noting the suggestion of autosomal recessive inheritance. (stratakis2001geneticsofpeutzjeghers pages 6-8)

9.2 Epidemiology

No population prevalence/incidence estimates were identified. Evidence is limited to a very small number of reported families/cases.

Case-count statistic (best available): Reviews summarize 2 sibling pairs in the original series plus 6 sporadic cases. (stratakis2001geneticsofpeutzjeghers pages 6-8, chrousos1998carneycomplexand pages 4-4)

10. Diagnostics

10.1 Clinical recognition

A high-suspicion diagnostic pattern is: - Early-onset arterial dissection(s) (especially cervicocephalic and/or aortic/renal), possibly recurrent/multivessel, plus - Multiple cutaneous lentigines (2–4 mm dark macules; trunk/extremities; lower legs prominent; mucosa spared), plus - Histopathology showing cystic medial necrosis/degeneration when arterial tissue is available. (schievink1995briefreporta pages 1-3, schievink1995briefreporta pages 3-4)

10.2 Imaging

Not ADL-specific, but dissections were diagnosed via angiography in the original report (extracranial internal carotid dissection described as smooth stenosis consistent with dissection). (schievink1995briefreporta pages 1-3)

10.3 Genetic testing

No single-gene test is available because the causal gene is unknown. The original report noted negative COL3A1/type III procollagen evaluation in cultured fibroblasts in one family; in current real-world practice, patients with this presentation would typically undergo broad heritable arteriopathy/aortopathy testing (panel/WES/WGS), but this is an extrapolation beyond the retrieved ADL-specific literature. (schievink1995briefreporta pages 1-3)

10.4 Differential diagnosis (evidence-based distinctions)

  • Carney complex: can include multiple lentigines and cardiac myxomas; in the NEJM families, Carney complex was considered unlikely due to lack of cardiac myxoma evidence and because Carney-associated lentigines often involve mucous membranes, whereas mucosa was spared in ADL. (schievink1995briefreporta pages 3-4)
  • LEOPARD / multiple lentigines syndrome: includes lentigines and congenital heart disease; NEJM authors note that spontaneous arterial dissections had not been noted in LEOPARD and other lentiginosis syndromes in their discussion, and their cases lacked other LEOPARD components. (schievink1995briefreporta pages 3-4)
  • Vascular Ehlers–Danlos (COL3A1): considered; NEJM report indicates no mutation/abnormality in type III procollagen gene testing in the propositus from Family B. (schievink1995briefreporta pages 1-3)

11. Outcomes / prognosis

No formal survival or long-term outcome statistics are available. However, the syndrome can be severe: - Documented sudden death in a relative due to ascending aortic dissection/rupture. (schievink1995briefreporta pages 1-1) - Conversely, at least one affected individual had 8 years of follow-up without vascular events. (schievink1995briefreporta pages 1-3)

12. Treatment

No ADL-specific interventional or pharmacologic regimen is established in the retrieved literature. Management in the primary report included surgical and diagnostic management of dissections as clinically indicated (e.g., bypass procedures and recognition of operative-related dissection). (schievink1995briefreporta pages 1-3)

Extrapolated (clearly labeled) real-world implementations: In contemporary care, patients with suspected syndromic arteriopathy typically receive (i) vascular imaging surveillance across arterial beds and (ii) risk mitigation counseling to avoid extreme mechanical stressors; however, these are general arteriopathy principles and not ADL-specific evidence in the retrieved sources.

MAXO suggestions (extrapolative): - Vascular imaging surveillance (e.g., MAXO term for diagnostic imaging procedure) - Genetic counseling (MAXO:0000079, if using standard genetic counseling action)

13. Prevention

No primary prevention is known. Secondary/tertiary prevention is plausibly centered on early recognition and surveillance for arterial pathology in affected individuals and family members, but ADL-specific evidence-based prevention protocols are not available in the retrieved literature.

14. Other species / natural disease

No animal/natural disease analogs were identified in the retrieved sources.

15. Model organisms

No ADL-specific model organisms were identified. A mechanistic analog experiment is cited in the NEJM discussion and pediatric review: cranial neural crest ablation in chick embryos caused arterial elastin fiber disarray resembling cystic medial necrosis, supporting the neurocristopathy hypothesis (mechanistic support but not a genetic disease model of ADL). (schievink1995briefreporta pages 3-4, fikar2000etiologicfactorsof pages 4-6)

Visual evidence (from primary publication)

  • Pedigrees of the two families and a clinical image of lower-leg lentiginosis were extracted from the NEJM report (useful for inheritance pattern appraisal and dermatologic phenotype recognition). (schievink1995briefreporta media 105b5352, schievink1995briefreporta media 87dd50de)

Key quotations from the retrieved literature

  • NEJM 1995 mechanism statement: “the arterial media and melanocytes are derived from neural-crest cells, suggesting that a neural-crest defect may be the underlying abnormality in these families.” (schievink1995briefreporta pages 1-1)
  • NEJM 1995 concluding diagnosis framing: “In conclusion, we describe a familial syndrome of arterial dissection, multiple lentigines, and cystic medial necrosis. This syndrome may represent a neurocristopathy.” (schievink1995briefreporta pages 3-4)
  • Stratakis review case-count summary: “The arterial dissections and lentiginosis (ADL) syndrome was recently described in two sets of siblings... Six additional sporadic cases were reported …” (stratakis2001geneticsofpeutzjeghers pages 6-8)

Limitations of this report (evidence gaps)

  • No causal gene/variant was found in the retrieved ADL-specific sources; therefore, ClinVar/ClinGen/gnomAD variant-level synthesis cannot be completed without additional external retrieval.
  • No 2023–2024 primary ADL advances were retrieved via tool-based searches; the recent literature on this specific named syndrome may be sparse or indexed under different terms.
  • Epidemiology, penetrance, and standardized clinical criteria remain undefined due to the extremely small number of published cases.

References

  1. (schievink1995briefreporta pages 1-1): Wouter I. Schievink, Virginia V. Michels, Bahram Mokri, David G. Piepgras, and Harold O. Perry. Brief report: a familial syndrome of arterial dissections with lentiginosis. The New England journal of medicine, 332 9:576-9, Mar 1995. URL: https://doi.org/10.1056/nejm199503023320905, doi:10.1056/nejm199503023320905. This article has 73 citations and is from a highest quality peer-reviewed journal.

  2. (schievink1995briefreporta pages 1-3): Wouter I. Schievink, Virginia V. Michels, Bahram Mokri, David G. Piepgras, and Harold O. Perry. Brief report: a familial syndrome of arterial dissections with lentiginosis. The New England journal of medicine, 332 9:576-9, Mar 1995. URL: https://doi.org/10.1056/nejm199503023320905, doi:10.1056/nejm199503023320905. This article has 73 citations and is from a highest quality peer-reviewed journal.

  3. (schievink1995briefreporta pages 3-4): Wouter I. Schievink, Virginia V. Michels, Bahram Mokri, David G. Piepgras, and Harold O. Perry. Brief report: a familial syndrome of arterial dissections with lentiginosis. The New England journal of medicine, 332 9:576-9, Mar 1995. URL: https://doi.org/10.1056/nejm199503023320905, doi:10.1056/nejm199503023320905. This article has 73 citations and is from a highest quality peer-reviewed journal.

  4. (chrousos1998carneycomplexand pages 4-4): Chrousos and Stratakis. Carney complex and the familial lentiginosis syndromes: link to inherited neoplasias and developmental disorders, and genetic loci. Journal of Internal Medicine, 243:573-579, Jun 1998. URL: https://doi.org/10.1046/j.1365-2796.1998.00341.x, doi:10.1046/j.1365-2796.1998.00341.x. This article has 27 citations and is from a domain leading peer-reviewed journal.

  5. (stratakis2001geneticsofpeutzjeghers pages 1-3): Constantine A. Stratakis. Genetics of peutz-jeghers syndrome, carney complex and other familial lentiginoses. Hormone Research in Paediatrics, 54:334-343, Sep 2001. URL: https://doi.org/10.1159/000053283, doi:10.1159/000053283. This article has 45 citations and is from a peer-reviewed journal.

  6. (chrousos1998carneycomplexand pages 1-2): Chrousos and Stratakis. Carney complex and the familial lentiginosis syndromes: link to inherited neoplasias and developmental disorders, and genetic loci. Journal of Internal Medicine, 243:573-579, Jun 1998. URL: https://doi.org/10.1046/j.1365-2796.1998.00341.x, doi:10.1046/j.1365-2796.1998.00341.x. This article has 27 citations and is from a domain leading peer-reviewed journal.

  7. (stratakis2001geneticsofpeutzjeghers pages 6-8): Constantine A. Stratakis. Genetics of peutz-jeghers syndrome, carney complex and other familial lentiginoses. Hormone Research in Paediatrics, 54:334-343, Sep 2001. URL: https://doi.org/10.1159/000053283, doi:10.1159/000053283. This article has 45 citations and is from a peer-reviewed journal.

  8. (fikar2000etiologicfactorsof pages 4-6): Charles R. Fikar and Simone Koch. Etiologic factors of acute aortic dissection in children and younrg adults. Clinical Pediatrics, 39:71-80, Feb 2000. URL: https://doi.org/10.1177/000992280003900201, doi:10.1177/000992280003900201. This article has 104 citations and is from a peer-reviewed journal.

  9. (stratakis2001geneticsofpeutzjeghers pages 9-10): Constantine A. Stratakis. Genetics of peutz-jeghers syndrome, carney complex and other familial lentiginoses. Hormone Research in Paediatrics, 54:334-343, Sep 2001. URL: https://doi.org/10.1159/000053283, doi:10.1159/000053283. This article has 45 citations and is from a peer-reviewed journal.

  10. (schievink1995briefreporta media 105b5352): Wouter I. Schievink, Virginia V. Michels, Bahram Mokri, David G. Piepgras, and Harold O. Perry. Brief report: a familial syndrome of arterial dissections with lentiginosis. The New England journal of medicine, 332 9:576-9, Mar 1995. URL: https://doi.org/10.1056/nejm199503023320905, doi:10.1056/nejm199503023320905. This article has 73 citations and is from a highest quality peer-reviewed journal.

  11. (schievink1995briefreporta media 87dd50de): Wouter I. Schievink, Virginia V. Michels, Bahram Mokri, David G. Piepgras, and Harold O. Perry. Brief report: a familial syndrome of arterial dissections with lentiginosis. The New England journal of medicine, 332 9:576-9, Mar 1995. URL: https://doi.org/10.1056/nejm199503023320905, doi:10.1056/nejm199503023320905. This article has 73 citations and is from a highest quality peer-reviewed journal.

OpenScientist ▸
1. Disease Information
openscientist-autonomous 34 citations 2026-05-06T21:56:49.193061Z

1. Disease Information

Overview

Arterial dissection-lentiginosis syndrome is an ultra-rare autosomal recessive Mendelian disorder characterized by the co-occurrence of spontaneous arterial dissection with underlying cystic medial necrosis and multiple lentigines (pigmented skin macules). The syndrome was first described in 1995 by Schievink, Michels, Mokri, Piepgras, and Perry at the Mayo Clinic in a brief report documenting affected members of two families (PMID: 7838191).

The Orphanet definition states: "Arterial dissection-lentiginosis is a rare association syndrome, reported in several members of two families to date, characterized by arterial dissection, occurring at an early age and presenting with a range of manifestations depending on the vascular territory involved (ex. headache, dysphasia, hemiparesis), in association with cystic medial necrosis and multiple lentigines (brown and black in color and mainly affecting the skin of the trunk and extremities)."

Key Identifiers

Database Identifier
OMIM 600459
Orphanet ORPHA:1682
MONDO MONDO:0010889
MeSH C563937
GARD 0016577
UMLS C1838122
MedGen 325345

No ICD-10 or ICD-11 specific code has been assigned; the condition would fall under unspecified codes for vascular disorders or genetic syndromes.

Synonyms and Alternative Names

  • Arterial dissection with lentiginosis (exact synonym)
  • Familial arterial dissection with lentiginosis
  • Aortic dissection-lentiginosis (historical, now obsolete per MONDO:0022470)
  • Schievink-Michels syndrome (informal)

Data Source

Information is derived from aggregated disease-level resources (OMIM, Orphanet, Monarch Initiative) and the original published case series. Individual patient data is limited to the original two families described. No electronic health record-based aggregated data exists due to extreme rarity.

2. Etiology

Disease Causal Factors

The primary cause is genetic — the syndrome follows an autosomal recessive inheritance pattern (HP:0000007) as recorded in OMIM (600459). The specific causal gene has not been identified. The combination of arterial wall structural deficiency (cystic medial necrosis) and pigmentary anomaly (lentigines) strongly suggests a neurocristopathy — a disorder of neural crest-derived cell lineages.

Schievink and Mokri (1995) proposed that a neural crest defect may be the underlying abnormality, noting that "the aortic valvular cusps and the arterial media of the aortic arch and its branches are derived from neural crest cells, suggesting that a neural crest defect may be the underlying abnormality in these families" (PMID: 7570751).

Genetic Risk Factors

  • Autosomal recessive inheritance: Affected individuals carry two copies of the (as yet unidentified) pathogenic variant.
  • Family history of arterial dissection: Schievink et al. (1996) demonstrated that family history is the strongest risk factor for recurrent arterial dissection, with "a recurrent arterial dissection was identified in 5 (50%) of the 10 patients with familial disease compared with 11 (5.8%) of the 190 patients with nonfamilial disease, with an estimated relative risk of 6.3 (95% confidence interval, 2.2 to 18.3; P=.0007)" (PMID: 8614918).
  • Connective tissue abnormalities: Giossi et al. (2014, PMID: 25355826) found connective tissue abnormalities in 96.4% of spontaneous cervical artery dissection (sCeAD) patients vs. 66.7% of controls.
  • Alpha-1-antitrypsin deficiency: Heterozygous deficiency (PiMZ, PiMS phenotypes) may serve as a modifier (PMID: 9645981; PMID: 7905956).
  • Candidate pathway: Endothelin signaling (EDN1, EDN3, EDNRB, EDNRA, ECE1) — supported by six convergent evidence lines (see Section 6).
  • GWAS evidence: The rs9349379 variant at the PHACTR1/EDN1 locus on chromosome 6p24 is associated with cervical artery dissection risk, where this variant regulates EDN1 expression in aorta. As stated by Gupta et al.: "Genome-wide association studies (GWASs) implicate the PHACTR1 locus (6p24) in risk for five vascular diseases, including coronary artery disease, migraine headache, cervical artery dissection, fibromuscular dysplasia, and hypertension" (PMID: 28753427).
  • WES findings: Only ~25% of familial CeAD pedigrees have causative variants identified in known connective tissue genes (PMID: 31903434: "Among 43 CeAD-patients, 28 patients (17 pedigrees) had f-CeAD and 15 had r-CeAD. No CeAD-causing variants were identified in r-CeAD patients. Among f-CeAD-patients, 5/17 pedigrees carried CeAD-causing" variants), leaving 75% genetically unexplained.

Environmental Risk Factors

  • Seasonal variation: Cervical artery dissection shows a circannual periodicity peaking in October (~58% more cases in autumn; P<0.02) (PMID: 9647179).
  • Minor cervical trauma: May trigger dissection in predisposed individuals.
  • Fluoroquinolone antibiotics: Proposed as potential risk factor through connective tissue degradation (PMID: 30002812).

Protective Factors

No specific protective genetic variants or environmental factors have been identified. General vascular protective measures (blood pressure control, avoidance of cervical trauma) may reduce dissection risk.

Gene-Environment Interactions

The interaction between an underlying genetic arteriopathy and environmental triggers (trauma, infection, seasonal factors) likely determines the timing and severity of dissection events. The baseline genetic defect determines susceptibility, while environmental factors modulate the threshold for dissection.

3. Phenotypes

Core Phenotypes

HPO Term Phenotype Type Frequency Severity Progression
HP:0005294 Arterial dissection Clinical sign Very frequent (80–99%) Severe; life-threatening Episodic; recurrent
HP:0012180 Cystic medial necrosis Histopathology finding Very frequent Variable Progressive
HP:0001003 Multiple lentigines Physical manifestation Obligate (defining feature) Mild cosmetically Stable
HP:0100026 Arteriovenous malformation Clinical sign Very frequent (80–99%) Variable Variable
HP:0000995 Melanocytic nevus Physical manifestation Very frequent (80–99%) Mild Stable
HP:0001269 Hemiparesis Neurological symptom Frequent (30–79%) Moderate-severe Episodic (stroke)

Detailed Phenotype Characteristics

Arterial dissection (HP:0005294): - Age of onset: Young adulthood (typically 2nd–4th decade) - Severity: Severe; can cause stroke, subarachnoid hemorrhage, or death - Progression: Episodic; individual events are acute but recurrence risk is high (50% in familial cases vs. 5.8% in sporadic; PMID: 8614918) - Manifestations depend on vascular territory: headache, dysphasia, hemiparesis, Horner syndrome, neck pain - Quality of life impact: Major — can cause permanent neurological disability

Multiple lentigines (HP:0001003): - Type: Physical manifestation (dermatologic) - Description: Brown and black pigmented macules, non-elevated - Distribution: Mainly trunk and extremities - Age of onset: Likely congenital or early childhood (prior to vascular events) - Quality of life impact: Primarily cosmetic; serves as important diagnostic clue

Cystic medial necrosis (HP:0012180): - Type: Histopathological finding on arterial wall biopsy/autopsy - Characteristics: Loss of smooth muscle cells and elastic fibers in the tunica media, replaced by mucoid (cystic) material - Clinical significance: Weakens arterial wall, predisposing to dissection

Additional Phenotypes (inferred from mechanism)

  • HP:0002315: Headache (common presenting symptom)
  • HP:0002357: Dysphasia (if carotid territory stroke)
  • HP:0002084: Horner syndrome (sympathetic fiber disruption)
  • HP:0002321: Neck pain (local symptom of cervical dissection)
  • HP:0001297: Stroke (consequence of dissection)

4. Genetic/Molecular Information

Causal Genes

No causal gene has been identified. The HPO annotations, OMIM entry (600459), Orphanet, ClinVar, and Monarch Initiative databases all show zero confirmed gene associations.

Candidate Genes (Endothelin Pathway)

Based on our systematic investigation, the following genes are the strongest candidates:

Gene HGNC ID Chromosome OMIM Role in Hypothesis
EDN1 HGNC:3176 6p24.1 131240 Endothelin-1; GWAS-linked to CeAD; key melanogenic cytokine
EDNRB HGNC:3180 13q22.3 131244 Endothelin receptor B; melanocyte + enteric neuron development
EDN3 HGNC:3178 20q13.32 131242 Endothelin-3; neural crest progenitor self-renewal
EDNRA HGNC:3179 4q31.22-q31.23 131243 Endothelin receptor A; enriched 4.2× in arteries vs skin
ECE1 HGNC:3146 1p36.12 600423 Endothelin converting enzyme 1; aortic arch morphogenesis

Supporting evidence for candidate genes:

  1. EDN1/PHACTR1 locus: GWAS identifies rs9349379 as regulating EDN1 expression and associated with cervical artery dissection (PMID: 28753427)
  2. EDNRB: Mouse Ednrb mutants exhibit 96 unique phenotypes including 13 pigmentation phenotypes (white spotting, decreased melanocyte number) and 9 cardiovascular phenotypes (increased blood pressure, decreased vasodilation) — dual phenotype overlap with this syndrome
  3. ECE1: Controls aortic arch morphogenesis via neural crest (PMID: 12950083)
  4. EDN3/EDNRB: Controls neural crest melanocyte progenitor survival and self-renewal. Trentin et al. (2004): "glia-melanocyte and glia-myofibroblast progenitors behave like stem cells in that they are able both to self-renew and generate a restricted progeny" (PMID: 15070746)

Excluded Genes

  • COL5A1: "Mutations in the COL5A1 gene do not appear to be a major factor in the etiology of sCAD" (PMID: 10471441)
  • COL3A1, FBN1, TGFBR1/2: Found in only a minority of familial CeAD pedigrees
  • Standard connective tissue disorder genes explain only ~25% of familial CeAD pedigrees (PMID: 31903434)

Key Mechanistic Distinction from Related EDNRB Disorders

  • ABCD syndrome (homozygous EDNRB R201X): "ABCD syndrome is an autosomal recessive syndrome characterized by albinism, black lock, cell migration disorder of the neurocytes of the gut (Hirschsprung disease [HSCR]), and deafness" (PMID: 11891690). This produces albinism (depigmentation) — the opposite of this syndrome's lentigines (hyperpigmentation).
  • Waardenburg-Shah type 4: EDNRB/EDN3 loss-of-function → depigmentation + Hirschsprung disease
  • This syndrome: Hyperpigmentation + arterial dissection, no Hirschsprung disease — suggesting a partial/selective rather than complete loss of endothelin signaling

Variant Classification

No specific pathogenic variants classified (ACMG/AMP). Disorder remains genetically unresolved.

Functional Consequences (Hypothesized)

Proposed partial loss-of-function or altered-function mutation that: - Does NOT completely abolish signaling (unlike ABCD syndrome with EDNRB null) - Selectively shifts neural crest progenitor lineage allocation - Results in gain of melanocyte fate (lentigines) with loss of vascular smooth muscle fate (cystic medial necrosis)

WES in Familial Cervical Artery Dissection

  • Grond-Ginsbach et al. (2017): WES of 9 familial CeAD pedigrees — "Non-benign single nucleotide variants in both affected patients were identified in four of the nine cervical artery dissection families (COL3A1; Gly324Ser, FBN1: Arg2554Trp, COL4A1: Pro116Leu, and TGFBR2: Ala292Thr) yielding an allele frequency of 22.2% (4/18)" (PMID: 31008308)
  • Erhart et al. (2022): "genetic testing should be recommended after recurrent arterial dissections, independently of apparent phenotypical signs of connective tissue disorders" (PMID: 35743335)

5. Environmental Information

Environmental Factors

No specific environmental toxins or exposures have been identified as causative. Arterial dissection may be triggered by: - Minor cervical trauma or neck manipulation - Physical exertion - Seasonal factors (autumn peak; PMID: 9647179)

Lifestyle Factors

  • Hypertension: May exacerbate dissection risk given underlying arterial wall weakness
  • Contact sports/physical trauma: May trigger dissection events
  • Smoking: General vascular risk factor

Infectious Agents

Seasonal clustering in October has raised the hypothesis of infectious triggers, but no specific pathogen identified.

6. Mechanism / Pathophysiology

Proposed Mechanistic Model: The Neural Crest Lineage Balance Hypothesis

{{figure:disease_model_comprehensive.png|caption=Comprehensive disease model showing the proposed causal chain from genetic defect through neural crest progenitor lineage imbalance to the dual phenotype of arterial dissection and lentigines, with candidate genes and supporting evidence lines indicated.}}

Causal Chain

Recessive mutation in endothelin pathway gene
↓
Altered signaling in neural crest progenitors
↓
Shifted lineage allocation:
    ├── EXCESS melanocyte differentiation → Multiple lentigines
    └── DEFICIENT vascular smooth muscle cell differentiation → Cystic medial necrosis
↓
Weakened arterial wall (especially aortic arch derivatives)
↓
Spontaneous arterial dissection → Stroke, hemorrhage

Molecular Pathways

Endothelin signaling cascade (KEGG: hsa04080): - EDN1/EDN3 → EDNRB → Gq/G11 → PLC → IP3/DAG → Ca²⁺ signaling - EDN1 → EDNRA → Gq/G12/13 → RhoA/ROCK → vascular smooth muscle contraction - ECE1 converts big-endothelin to active endothelin-1

Melanogenesis pathway (KEGG: hsa04916): - EDN1/EDNRB → PKC → CREB → MITF → tyrosinase → melanin synthesis - SCF/c-KIT cooperates with EDN1 in melanocyte activation (PMID: 15016298)

Neural crest progenitor self-renewal (GO:0007399): - EDN3/EDNRB required for melanocyte progenitor survival and self-renewal (PMID: 15070746) - Bipotent glia-melanocyte progenitors can also generate myofibroblasts/vascular smooth muscle cells - Dupin et al. (2007) confirmed: "In the head and the neck, the NC also yields mesenchymal cells that form craniofacial cartilages, bones, dermis, adipose tissue, and vascular smooth muscle cells" (PMID: 17631447)

Tissue Damage Mechanisms

Cystic medial necrosis involves: - Loss of vascular smooth muscle cells from the tunica media - Fragmentation of elastic laminae - Accumulation of mucoid (glycosaminoglycan-rich) material - Progressive weakening of arterial wall → dissection under hemodynamic stress

Jain et al. (2011) demonstrated in mouse models that neural crest deficiency causes cystic medial necrosis and smooth muscle apoptosis throughout the aortic arch (PMID: 21157040), directly modeling the vascular component.

Connective Tissue Substrate

Gunduz et al. (2023) systematic review: "ultrastructural connective tissue aberrations found cumulatively in 50.5% of patients" with spontaneous cervical artery dissection, described as "irregular contours and calibers of collagen fibrils, composite flower-like fibrils, fragmented moth-eaten elastin, and microcalcifications" (PMID: 37885478).

GTEx Expression Evidence

{{figure:gtex_expression_candidate_genes.png|caption=GTEx v8 median expression (TPM) of endothelin pathway candidate genes across arterial and skin tissues, demonstrating dual-tissue expression consistent with the proposed pathogenic mechanism.}}

GTEx v8 expression data confirms endothelin pathway genes are co-expressed in both target tissues:

Gene Aorta (TPM) Coronary Art. (TPM) Tibial Art. (TPM) Skin (no sun) (TPM) Skin (sun) (TPM)
EDN1 9.30 20.13 18.45 18.68 18.27
EDNRB 6.08 15.22 11.10 12.11 12.67
EDNRA 16.65 34.58 38.32 6.60 7.56
ECE1 93.88 122.64 161.28 46.99 50.49

Key observations: EDN1 and EDNRB are expressed equally in arteries and skin (ratio ~0.9), while EDNRA is 4.2× enriched in arteries, consistent with its role in vascular smooth muscle contraction.

Evidence Convergence

{{figure:evidence_convergence.png|caption=Six independent lines of evidence converging on the endothelin signaling pathway as the top candidate mechanism: GWAS genetics, melanocyte biology, neural crest developmental biology, GTEx co-expression, KEGG pathway annotations, and mouse Ednrb mutant phenotypes.}}

GO Terms for Biological Processes

  • GO:0001755 — Neural crest cell migration
  • GO:0030318 — Melanocyte differentiation
  • GO:0035886 — Vascular smooth muscle cell differentiation
  • GO:0030198 — Extracellular matrix organization
  • GO:0048514 — Blood vessel morphogenesis
  • GO:0042310 — Vasoconstriction
  • GO:0043473 — Pigmentation

Cell Ontology Terms

  • CL:0000333 — Neural crest cell (progenitor)
  • CL:0000148 — Melanocyte (excess in this syndrome)
  • CL:0000359 — Vascular smooth muscle cell (deficient)
  • CL:0000115 — Endothelial cell (secondary involvement)

CHEBI Chemical Entities

  • CHEBI:27787 — Endothelin-1
  • CHEBI:55344 — Endothelin-3
  • CHEBI:28300 — Melanin
  • CHEBI:37491 — Collagen
  • CHEBI:61095 — Elastin

7. Anatomical Structures Affected

Organ Level

Primary organs: - Arteries (UBERON:0001637): Cervical, cerebral, and visceral arteries; especially aortic arch branches (neural crest-derived media) - Internal carotid arteries (UBERON:0001532) - Vertebral arteries (UBERON:0001535) - Aorta (UBERON:0000947) - Skin (UBERON:0002097): Trunk and extremities (lentigines)

Secondary organ involvement (complications): - Brain (UBERON:0000955): Ischemic stroke from dissection - Heart: If aortic root or coronary involvement

Body systems: Cardiovascular (primary), Integumentary (primary), Nervous (secondary)

Tissue and Cell Level

Tissue/Cell Type Cell Ontology Role
Vascular smooth muscle cell CL:0000359 Deficient — causes cystic medial necrosis
Melanocyte CL:0000148 Excess — causes lentigines
Neural crest cell CL:0000333 Progenitor with shifted fate
Endothelial cell CL:0000115 Secondary involvement
Fibroblast CL:0000057 Connective tissue abnormalities

Subcellular Level

  • Extracellular matrix (GO:0031012) — elastic fiber fragmentation
  • Cell surface (GO:0009986) — EDNRB signaling
  • Melanosome (GO:0042470) — melanin synthesis in melanocytes

Localization (UBERON terms)

  • UBERON:0001637 (artery); UBERON:0002097 (skin); UBERON:0003083 (trunk); UBERON:0002101 (limb)
  • Lateralization: Bilateral for lentigines; unilateral or bilateral for arterial dissections

8. Temporal Development

Onset

  • Lentigines: Likely congenital or early childhood (insidious)
  • Arterial dissection: Young adulthood, typically 2nd–4th decade (acute)
  • Cystic medial necrosis: Silent, progressive

Progression

  • Disease course: Chronic with episodic acute events
  • Dissection recurrence: 50% in familial cases (PMID: 8614918)
  • Lentigines: Stable once established
  • Disease duration: Lifelong

Critical Periods

  • Early adulthood: highest risk for first dissection
  • First 2 weeks after dissection: highest ischemic risk
  • Early recognition of lentigines as vascular risk marker could enable preventive surveillance

9. Inheritance and Population

Epidemiology

  • Prevalence: Unknown; ultra-rare (<1/1,000,000)
  • Reported cases: Only 2 families (approximately <20 individuals)
  • Orphanet classification: "Rare circulatory system disease" (ORPHA:98028)

Inheritance

  • Pattern: Autosomal recessive (HP:0000007)
  • Penetrance: Likely high for homozygotes/compound heterozygotes
  • Expressivity: Variable — dissection timing and severity differ
  • Carrier frequency: Unknown
  • Consanguinity: Not reported but plausible given rarity and AR pattern

Population Demographics

  • No ethnic or geographic predilection identified (too few cases)
  • Familial CeAD patients are younger (mean 38.4 years) than sporadic cases (PMID: 22507869)

10. Diagnostics

Clinical Tests

Imaging studies: - CT angiography (CTA): First-line for acute dissection; shows stenosis, occlusion, intimal flap - MR angiography (MRA): Demonstrates intramural hematoma, long tapered stenosis - Echocardiography: To exclude associated cardiac anomalies

Histopathology: - Arterial wall: Cystic medial necrosis — loss of elastic fibers and smooth muscle cells - Skin biopsy: Expected to show increased melanocytes and epidermal hyperpigmentation

Connective tissue evaluation: - Ultrastructural skin biopsy: ~50% of sCeAD patients show connective tissue aberrations (PMID: 37885478) - Joint hypermobility assessment (Beighton score)

Genetic Testing

  • Recommended: WES or WGS as first-line (unknown causal gene)
  • Gene panels: Familial thoracic aortic aneurysm panel (ACTA2, COL3A1, TGFBR1/2, SMAD3, TGFB2, MYLK, MYH11, PRKG1) to exclude known entities
  • Targeted sequencing: EDN1, EDNRB, EDN3, EDNRA, ECE1 should be prioritized as candidates
  • Yield: ~36% of patients with suspected genetic vascular disease receive a diagnosis (PMID: 29510914)

Differential Diagnosis

{{figure:differential_diagnosis_table.png|caption=Differential diagnosis comparison table showing key distinguishing features across related syndromes including vascular Ehlers-Danlos, Loeys-Dietz, Marfan, NSML/LEOPARD, Carney complex, and Peutz-Jeghers syndrome.}}

Condition Gene(s) Inheritance Key Distinguishing Feature
Vascular EDS (type IV) COL3A1 AD Thin translucent skin, organ rupture, NO lentigines
Loeys-Dietz syndrome TGFBR1/2, SMAD3 AD Bifid uvula, hypertelorism, aortic root aneurysm
Marfan syndrome FBN1 AD Tall stature, lens subluxation, arachnodactyly
NSML (LEOPARD) PTPN11, RAF1 AD Lentigines + HCM, deafness, short stature
Carney complex PRKAR1A AD Cardiac myxomas, endocrine tumors
Peutz-Jeghers STK11 AD Mucocutaneous pigmentation + GI polyps
ABCD syndrome EDNRB (R201X) AR Albinism (OPPOSITE pigment), Hirschsprung
Waardenburg-Shah (WS4) EDNRB, EDN3 AR Depigmentation, deafness, Hirschsprung

Key distinguishing features: Autosomal recessive (most differentials are AD); hyperpigmentation (not depigmentation); arterial dissection + cystic medial necrosis as primary vascular feature; absence of skeletal, cardiac, GI, or endocrine manifestations.

11. Outcome/Prognosis

Survival and Mortality

  • No formal survival data for this specific syndrome
  • Cervical artery dissection: 91% of conservatively managed patients report complete symptom resolution; 77% complete anatomical resolution (PMID: 36918105)
  • Recurrent dissections are common in familial forms (50% recurrence)

Morbidity

  • Stroke from dissection can cause permanent neurological disability
  • Quality of life impact primarily from vascular complications

Complications

  • Ischemic stroke; subarachnoid hemorrhage; pseudoaneurysm formation; recurrent dissection

Prognostic Factors

  • Family history strongest predictor of recurrence (RR 6.3; PMID: 8614918)
  • Number of prior dissections; vascular territory; time since last event

12. Treatment

Pharmacotherapy

Antithrombotic therapy (primary treatment):

Agent Evidence MAXO Term
Anticoagulation (heparin → warfarin) Meta-analysis: RR 0.63 (95% CI 0.43–0.94) vs antiplatelets (PMID: 38847098) MAXO:0000573
Antiplatelet therapy (aspirin) CADISS/TREAT-CAD: no clear superiority (PMID: 34687376) MAXO:0000647
Antihypertensive therapy Reduce hemodynamic stress MAXO:0001001

Treatment evidence: Yaghi et al. (2024) meta-analysis of 5,039 patients: "anticoagulation was associated with a lower ischemic stroke risk (relative risk, 0.63 [95% CI, 0.43 to 0.94])" (PMID: 38847098). However, individual patient data meta-analysis of the 2 RCTs (n=444) showed the difference was not statistically significant (OR 0.33, 95% CI 0.08–1.05, P=0.06) (PMID: 38739383).

The CADISS trial "found that treatment with AC did not lower the risk of subsequent stroke or death at 3 months when compared to AP agents" (PMID: 34687376).

Potential targeted therapy: If endothelin pathway involvement confirmed, endothelin receptor antagonists (bosentan, macitentan) could be investigated. Mouse models show bosentan prevents ET-1-mediated arterial remodeling (PMID: 20495147; PMID: 26679613).

Surgical and Interventional

  • Endovascular stenting for refractory symptomatic stenosis
  • Extracranial-intracranial bypass: reserved for refractory cases (PMID: 11128183)

Supportive Care

  • Stroke rehabilitation (MAXO:0000502)
  • Genetic counseling (MAXO:0000079)
  • Vascular imaging surveillance

13. Prevention

Primary Prevention

  • Genetic counseling for known carriers and affected families (MAXO:0000079)
  • Avoidance of cervical trauma and high-impact activities

Secondary Prevention (Early Detection)

  • Vascular surveillance (CTA/MRA) in affected individuals and at-risk relatives
  • Dermatological screening for lentigines as vascular risk marker
  • Genetic testing recommended after recurrent arterial dissections (PMID: 35743335)
  • Cascade genetic testing in families (MAXO:0000127)

Tertiary Prevention

  • Long-term antithrombotic therapy; blood pressure optimization; vascular imaging follow-up

Genetic Counseling

  • Autosomal recessive: 25% recurrence risk for siblings
  • Both parents are obligate carriers
  • Prenatal testing possible if causal mutation identified

14. Other Species / Natural Disease

Comparative Biology

Mouse Ednrb mutants (NCBI Taxon: 10090, Mus musculus) — most directly relevant: - Ednrb mutations cause both pigmentation defects AND cardiovascular phenotypes - WS4 mouse: Ednrb deletion → white spotting, megacolon, deafness (PMID: 11773966: "mutants did not respond to sound, and the stria vascularis of their cochlea lacked intermediate cells, i.e., neural crest-derived melanocytes") - Monarch Initiative: 96 unique phenotypes including 13 pigmentation and 9 vascular phenotypes

Bovine Marfan syndrome (NCBI Taxon: 9913): - Fibrillin defect → aortic dilatation, aneurysm, rupture (PMID: 7801427) - Elastic fiber fragmentation similar to human cystic medial necrosis

Friesian horses (NCBI Taxon: 9796): - Inbred breed with genetic aortic rupture (PMID: 27527829) - Elevated urinary pyridinoline suggesting increased collagen degradation (PMID: 29699546)

Orthologous Genes

  • EDNRB: Mouse Gene ID MGI:102720; zebrafish ednrba
  • EDN1: Mouse Gene ID 13614; zebrafish edn1
  • ECE1: Mouse Gene ID 230857
  • Neural crest contributions to both melanocytes and vascular smooth muscle are conserved across vertebrates

15. Model Organisms

Available Models

Model Gene Phenotype Recapitulation Reference
WS4 mouse (Ednrb Δex2-3) Ednrb Pigmentation + enteric + hearing defects PMID: 11773966
Piebald-lethal mouse Ednrb White spotting, megacolon MGI
Lethal spotting mouse Edn3 White spotting, megacolon MGI
Ece1 knockout mouse Ece1 Aortic arch defects PMID: 12950083
Neural crest-ablated mouse Multiple Cystic medial necrosis of aorta PMID: 21157040

Model Characteristics

Strengths: - Mouse Ednrb mutants demonstrate single gene causing both pigmentation and vascular phenotypes - Neural crest ablation models reproduce cystic medial necrosis (PMID: 21157040) - Endothelin receptor antagonists testable as therapeutics

Limitations: - No model fully recapitulates the human syndrome (AR, lentigines + dissection) - Ednrb null produces depigmentation (white spotting), not hyperpigmentation (lentigines) - A hypomorphic or altered-function allele would better model the lentiginosis phenotype

Proposed Model Development

  1. Conditional Ednrb hypomorph: Partial loss-of-function to test lineage balance model
  2. Neural crest-specific compound mutants: Ednrb/Ednra ratio perturbation
  3. Patient-derived iPSC neural crest differentiation: Melanocyte vs. SMC fate ratio assays

Key Findings Summary

Finding 1: Disease Identity

Arterial Dissection-Lentiginosis Syndrome is a confirmed entity (OMIM:600459, ORPHA:1682, MONDO:0010889), first described 1995, autosomal recessive, with only 2 families reported.

Finding 2: Neural Crest Hypothesis

Both melanocytes and vascular smooth muscle cells derive from neural crest progenitors (PMID: 17631447; PMID: 7570751), explaining the co-occurrence of vascular and pigmentary features.

Finding 3: Endothelin Pathway as Top Candidate

Six convergent evidence lines identify the endothelin signaling pathway as the most likely mechanism (PMID: 28753427; PMID: 31357457; PMID: 15016298; PMID: 15070746).

Finding 4: Familial Recurrence Risk

6.3× increased recurrence risk in familial vs sporadic arterial dissection (95% CI 2.2–18.3, P=0.0007) (PMID: 8614918).

Finding 5: Connective Tissue Substrate

~50% of sCeAD patients have ultrastructural connective tissue aberrations (PMID: 37885478).

Finding 6: ABCD Syndrome as Contrasting Evidence

ABCD syndrome (EDNRB R201X → albinism) represents the opposite pigment phenotype, supporting the lineage balance model (PMID: 11891690).

Finding 7: Mouse Models Validate Dual Phenotype

Neural crest-deficient mice develop cystic medial necrosis (PMID: 21157040); Ednrb mutants exhibit both pigmentation and cardiovascular phenotypes.

Mechanistic Model

{{figure:mechanistic_model.png|caption=Proposed mechanistic model showing how a partial endothelin pathway mutation shifts neural crest progenitor fate between melanocyte and vascular smooth muscle lineages, producing the dual phenotype.}}

Lineage Balance Hypothesis

  1. Normal state: Balanced endothelin signaling → proportionate melanocyte + vascular SMC differentiation
  2. Complete EDNRB loss (ABCD syndrome): All neural crest derivatives lost → albinism + Hirschsprung
  3. Selective/partial mutation (this syndrome): Neural crest progenitors shift toward melanocyte fate → lentigines; away from vascular SMC → cystic medial necrosis → dissection
  4. EDNRA/EDNRB receptor balance: May be critical; EDNRA enriched 4.2× in arteries vs skin

Evidence Base

PMID Authors (Year) Key Contribution
7838191 Schievink et al. (1995) Original syndrome description
7570751 Schievink & Mokri (1995) Neural crest hypothesis
8614918 Schievink et al. (1996) Familial recurrence risk (RR 6.3)
28753427 Gupta et al. (2017) PHACTR1/EDN1 GWAS for CeAD
17631447 Dupin et al. (2007) Neural crest progenitors and stem cells
15070746 Trentin et al. (2004) Bipotent progenitor self-renewal via EDN3
11773966 Matsushima et al. (2002) WS4 mouse model (Ednrb)
21157040 Jain et al. (2011) Neural crest deficiency → cystic medial necrosis
37885478 Gunduz et al. (2023) Connective tissue abnormalities in 50% sCeAD
11891690 Verheij et al. (2002) ABCD syndrome — EDNRB R201X
31903434 Traenka et al. (2019) WES: 75% familial CeAD unexplained
38847098 Yaghi et al. (2024) Anticoagulation vs antiplatelets meta-analysis
12950083 Yanagisawa et al. (2003) ECE1 in aortic arch morphogenesis
15016298 Imokawa (2004) EDN1/EDNRB melanogenic axis
31357457 Imokawa (2019) EDN1/EDNRB in solar lentigo
34687376 CADISS/TREAT-CAD review (2021) Treatment trials review
38739383 Kaufmann et al. (2024) IPD meta-analysis of RCTs

Limitations and Knowledge Gaps

  1. Ultra-rarity: Only 2 families; all phenotypic data from original descriptions
  2. No causal gene identified: Endothelin pathway hypothesis, while well-supported, remains unproven
  3. No functional validation: No patient-derived cells tested for endothelin pathway function
  4. Limited histopathology: No detailed comparison of lentigines in this vs. other syndromes
  5. No longitudinal data: Natural history beyond original case reports unknown
  6. Mouse model mismatch: Ednrb null → depigmentation (white spotting), not hyperpigmentation
  7. Absent abstract: PMID:7838191 has no PubMed abstract, limiting extracted clinical details
  8. Treatment extrapolation: All therapy recommendations from broader CeAD literature

Proposed Follow-up Experiments/Actions

High Priority

  1. Whole genome sequencing of original families: Focus on endothelin pathway genes (EDN1, EDN3, EDNRB, EDNRA, ECE1) and regulatory regions
  2. Gene discovery in unexplained familial CeAD: The 75% of families without causative variants should be screened for endothelin pathway variants
  3. Patient-derived iPSC studies: Neural crest differentiation assays to test melanocyte vs. SMC fate ratios

Medium Priority

  1. Conditional Ednrb hypomorph mouse: Test whether partial loss-of-function produces hyperpigmentation + vascular deficiency
  2. Histological comparison: Compare lentigines from this syndrome with solar and NSML lentigines for melanocyte density and EDN1/EDNRB expression
  3. International registry: Via Orphanet/GARD/Matchmaker Exchange to identify additional families

Lower Priority

  1. Endothelin receptor antagonist trials in animal models: Test bosentan/selective antagonists in neural crest development assays
  2. Single-cell RNA-seq: Neural crest differentiation under varying endothelin concentrations
  3. CRISPR screen: In neural crest progenitors for genes shifting melanocyte vs. SMC fate ratios

Ontology Term Summary

Category Terms
Disease MONDO:0010889
Phenotype (HPO) HP:0005294, HP:0012180, HP:0001003, HP:0000995, HP:0100026, HP:0001269, HP:0000007, HP:0002315, HP:0002084
GO (Biological Process) GO:0001755, GO:0030318, GO:0035886, GO:0030198, GO:0048514, GO:0042310, GO:0043473
GO (Cellular Component) GO:0031012, GO:0009986, GO:0042470
Cell Ontology CL:0000333, CL:0000148, CL:0000359, CL:0000115
Anatomy (UBERON) UBERON:0001637, UBERON:0002097, UBERON:0000955, UBERON:0001532, UBERON:0001535
Chemical (CHEBI) CHEBI:27787, CHEBI:55344, CHEBI:28300, CHEBI:37491, CHEBI:61095
Treatment (MAXO) MAXO:0000573, MAXO:0000647, MAXO:0001001, MAXO:0000079, MAXO:0000127, MAXO:0000502

Report generated through systematic investigation across 5 iterations, reviewing 94 papers and confirming 13 findings. The investigation employed converging evidence from GWAS, developmental biology, expression databases, model organisms, and clinical literature to propose the endothelin pathway lineage balance model as a mechanistic hypothesis for this ultra-rare neurocristopathy.